Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is effective in patients with advanced B-cell acute lymphoblastic leukemia (B-ALL). However, efficacy data is sparse in subgroups of patients with high-risk features such as BCR-ABL(+), TP53 mutation, extramedullary disease (including central...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Blood Adv
Prif Awduron: Zhang, Xian, Lu, Xin-an, Yang, Junfang, Zhang, Gailing, Li, Jingjing, Song, Lisong, Su, Yunchao, Shi, Yanze, Zhang, Min, He, Jiujiang, Song, Dan, Lv, Fanyong, Li, Wenqian, Wu, Yan, Wang, Hui, Liu, Hongxing, Zhou, Xiaosu, He, Ting, Lu, Peihua
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2020
Pynciau:
Immunobiology and Immunotherapy
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7252549/
https://ncbi.nlm.nih.gov/pubmed/32453841
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020001466
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg